{"context":{"query":">>chembl_molecule>>clinical_trials","source_dataset":"chembl_molecule","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":36,"mapped":1},"pagination":{"has_next":false},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"CHEMBL4297517","source":"CHEMBL4297517|MAVACAMTEN","targets":["NCT06112743|A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy|ACTIVE_NOT_RECRUITING|PHASE4|INTERVENTIONAL","NCT07004972|A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)|RECRUITING|PHASE4|INTERVENTIONAL","NCT07103655|The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction|NOT_YET_RECRUITING|PHASE4|INTERVENTIONAL","NCT03470545|Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy|COMPLETED|PHASE3|INTERVENTIONAL","NCT03723655|A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT04349072|A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy|COMPLETED|PHASE3|INTERVENTIONAL","NCT05174416|A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM|COMPLETED|PHASE3|INTERVENTIONAL","NCT05414175|A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy|COMPLETED|PHASE3|INTERVENTIONAL","NCT05582395|A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy|COMPLETED|PHASE3|INTERVENTIONAL","NCT06253221|A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT02842242|A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction|COMPLETED|PHASE2|INTERVENTIONAL","NCT03442764|A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)|COMPLETED|PHASE2|INTERVENTIONAL","NCT03496168|Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER|COMPLETED|PHASE2|INTERVENTIONAL","NCT04766892|A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT|COMPLETED|PHASE2|INTERVENTIONAL","NCT02329184|Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461|COMPLETED|PHASE1|INTERVENTIONAL","NCT02356289|Single Ascending Dose Study of MYK-461 in Healthy Volunteers|COMPLETED|PHASE1|INTERVENTIONAL","NCT02480296|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of MYK-461 in Healthy Volunteers|COMPLETED|PHASE1|INTERVENTIONAL","NCT05135871|Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects|COMPLETED|PHASE1|INTERVENTIONAL","NCT05320094|A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants|COMPLETED|PHASE1|INTERVENTIONAL","NCT05362045|A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants|COMPLETED|PHASE1|INTERVENTIONAL","NCT05719805|A Study to Evaluate the Effects of Mavacamten in Healthy Participants|COMPLETED|PHASE1|INTERVENTIONAL","NCT05489705|A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)|RECRUITING|nan|OBSERVATIONAL","NCT05939700|Mavacamten Pregnancy Surveillance Program|RECRUITING|nan|OBSERVATIONAL","NCT06023186|Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM|RECRUITING|nan|OBSERVATIONAL","NCT06146660|A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy|RECRUITING|nan|OBSERVATIONAL","NCT06338202|Real-World Effectiveness of Mavacamten in Canada|COMPLETED|nan|OBSERVATIONAL","NCT06372457|COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)|ACTIVE_NOT_RECRUITING|nan|OBSERVATIONAL","NCT06549608|A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada|ACTIVE_NOT_RECRUITING|nan|OBSERVATIONAL","NCT06551129|Real-world Patient Reported Outcomes Among Patients Treated With Camzyos|RECRUITING|nan|OBSERVATIONAL","NCT06856265|Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy|NOT_YET_RECRUITING|nan|INTERVENTIONAL","NCT06947590|Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy|ACTIVE_NOT_RECRUITING|nan|INTERVENTIONAL","NCT07107373|A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US|ACTIVE_NOT_RECRUITING|nan|OBSERVATIONAL","NCT07120776|Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial|NOT_YET_RECRUITING|nan|INTERVENTIONAL","NCT07168655|Mavacamten in Obstructive Hypertrophic Cardiomyopathy|COMPLETED|nan|OBSERVATIONAL","NCT07361289|A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China|RECRUITING|nan|OBSERVATIONAL","NCT07383025|Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan|RECRUITING|nan|OBSERVATIONAL"]}]}